Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.16
RTIX's Cash to Debt is ranked lower than
54% of the 519 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. RTIX: 0.16 )
RTIX' s 10-Year Cash to Debt Range
Min: 0.09   Max: N/A
Current: 0.16

Equity to Asset 0.45
RTIX's Equity to Asset is ranked higher than
55% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. RTIX: 0.45 )
RTIX' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.9
Current: 0.45

0.3
0.9
Interest Coverage 4.15
RTIX's Interest Coverage is ranked lower than
57% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 365.56 vs. RTIX: 4.15 )
RTIX' s 10-Year Interest Coverage Range
Min: 4.15   Max: 58.56
Current: 4.15

4.15
58.56
F-Score: 6
Z-Score: 1.48
M-Score: -2.48
WACC vs ROIC
13.99%
4.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.66
RTIX's Operating margin (%) is ranked higher than
76% of the 494 Companies
in the Global Medical Devices industry.

( Industry Median: 4.98 vs. RTIX: 5.66 )
RTIX' s 10-Year Operating margin (%) Range
Min: -76.65   Max: 10.76
Current: 5.66

-76.65
10.76
Net-margin (%) 3.24
RTIX's Net-margin (%) is ranked higher than
73% of the 494 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. RTIX: 3.24 )
RTIX' s 10-Year Net-margin (%) Range
Min: -77.87   Max: 8.42
Current: 3.24

-77.87
8.42
ROE (%) 5.22
RTIX's ROE (%) is ranked higher than
75% of the 488 Companies
in the Global Medical Devices industry.

( Industry Median: 4.73 vs. RTIX: 5.22 )
RTIX' s 10-Year ROE (%) Range
Min: -57.28   Max: 10.14
Current: 5.22

-57.28
10.14
ROA (%) 2.35
RTIX's ROA (%) is ranked higher than
74% of the 522 Companies
in the Global Medical Devices industry.

( Industry Median: 1.71 vs. RTIX: 2.35 )
RTIX' s 10-Year ROA (%) Range
Min: -44.6   Max: 5.68
Current: 2.35

-44.6
5.68
ROC (Joel Greenblatt) (%) 7.57
RTIX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 517 Companies
in the Global Medical Devices industry.

( Industry Median: 7.57 vs. RTIX: 7.57 )
RTIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -92.51   Max: 32.86
Current: 7.57

-92.51
32.86
Revenue Growth (3Y)(%) 14.80
RTIX's Revenue Growth (3Y)(%) is ranked higher than
91% of the 352 Companies
in the Global Medical Devices industry.

( Industry Median: 4.20 vs. RTIX: 14.80 )
RTIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22.5   Max: 14.8
Current: 14.8

-22.5
14.8
EBITDA Growth (3Y)(%) 0.90
RTIX's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. RTIX: 0.90 )
RTIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49   Max: 128.9
Current: 0.9

-49
128.9
» RTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

RTIX Guru Trades in Q2 2014

Chuck Royce 2,234,448 sh (-1.26%)
Jim Simons 26,600 sh (-70.01%)
» More
Q3 2014

RTIX Guru Trades in Q3 2014

Chuck Royce 1,907,948 sh (-14.61%)
Jim Simons 22,500 sh (-15.41%)
» More
Q4 2014

RTIX Guru Trades in Q4 2014

Jim Simons 24,500 sh (+8.89%)
Chuck Royce 1,789,548 sh (-6.21%)
» More
Q1 2015

RTIX Guru Trades in Q1 2015

Jim Simons 65,000 sh (+165.31%)
Chuck Royce 1,508,774 sh (-15.69%)
» More
» Details

Insider Trades

Latest Guru Trades with RTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 64.60
RTIX's P/E(ttm) is ranked higher than
73% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. RTIX: 64.60 )
RTIX' s 10-Year P/E(ttm) Range
Min: 19.81   Max: 318.33
Current: 64.6

19.81
318.33
Forward P/E 28.65
RTIX's Forward P/E is ranked higher than
77% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. RTIX: 28.65 )
N/A
PE(NRI) 66.30
RTIX's PE(NRI) is ranked higher than
79% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. RTIX: 66.30 )
RTIX' s 10-Year PE(NRI) Range
Min: 19.81   Max: 318.33
Current: 66.3

19.81
318.33
P/B 3.30
RTIX's P/B is ranked higher than
71% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 3.93 vs. RTIX: 3.30 )
RTIX' s 10-Year P/B Range
Min: 0.27   Max: 3.4
Current: 3.3

0.27
3.4
P/S 1.40
RTIX's P/S is ranked higher than
84% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. RTIX: 1.40 )
RTIX' s 10-Year P/S Range
Min: 0.62   Max: 4.34
Current: 1.4

0.62
4.34
POCF 30.95
RTIX's POCF is ranked higher than
82% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. RTIX: 30.95 )
RTIX' s 10-Year POCF Range
Min: 3.56   Max: 237.8
Current: 30.95

3.56
237.8
EV-to-EBIT 32.04
RTIX's EV-to-EBIT is ranked higher than
82% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 568.20 vs. RTIX: 32.04 )
RTIX' s 10-Year EV-to-EBIT Range
Min: -195.9   Max: 2390.3
Current: 32.04

-195.9
2390.3
Current Ratio 3.31
RTIX's Current Ratio is ranked higher than
75% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. RTIX: 3.31 )
RTIX' s 10-Year Current Ratio Range
Min: 1   Max: 5.91
Current: 3.31

1
5.91
Quick Ratio 1.36
RTIX's Quick Ratio is ranked higher than
59% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. RTIX: 1.36 )
RTIX' s 10-Year Quick Ratio Range
Min: 0.49   Max: 3.07
Current: 1.36

0.49
3.07
Days Inventory 320.88
RTIX's Days Inventory is ranked higher than
59% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 172.71 vs. RTIX: 320.88 )
RTIX' s 10-Year Days Inventory Range
Min: 75.71   Max: 366.78
Current: 320.88

75.71
366.78
Days Sales Outstanding 53.60
RTIX's Days Sales Outstanding is ranked higher than
87% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 86.69 vs. RTIX: 53.60 )
RTIX' s 10-Year Days Sales Outstanding Range
Min: 28.72   Max: 81.26
Current: 53.6

28.72
81.26

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.90
RTIX's Price/Tangible Book is ranked higher than
64% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 7.69 vs. RTIX: 11.90 )
RTIX' s 10-Year Price/Tangible Book Range
Min: 0.97   Max: 6.68
Current: 11.9

0.97
6.68
Price/DCF (Projected) 2.30
RTIX's Price/DCF (Projected) is ranked higher than
84% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. RTIX: 2.30 )
RTIX' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 36.25
Current: 2.3

0.82
36.25
Price/Median PS Value 1.00
RTIX's Price/Median PS Value is ranked higher than
83% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. RTIX: 1.00 )
RTIX' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 3.05
Current: 1

0.65
3.05
Price/Graham Number 2.80
RTIX's Price/Graham Number is ranked higher than
82% of the 582 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. RTIX: 2.80 )
RTIX' s 10-Year Price/Graham Number Range
Min: 1.03   Max: 4.19
Current: 2.8

1.03
4.19
Earnings Yield (Greenblatt) 3.10
RTIX's Earnings Yield (Greenblatt) is ranked higher than
78% of the 507 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. RTIX: 3.10 )
RTIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.8
Current: 3.1

0.1
8.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RT2.Germany,
RTI Surgical Inc, formerly RTI Biologics, Inc., was incorporated in 1997 in Florida as a wholly-owned subsidiary of the University of Florida Tissue Bank. The Company process donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing proprietary BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Company process tissue at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany, and manufacture metal and synthetic implants in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and services in all 50 states and in over 45 countries. Its lines of business are comprised primarily of six categories: spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental and ortho fixation. It has developed and utilized in the United States the patented BioCleanse tissue sterilization process, which is an automated, pharmaceutical grade chemical sterilization process for musculoskeletal bone and certain soft tissue. The TUTOPLAST tissue sterilization process utilizes solvent dehydration and chemical inactivation to remove blood, lipids and extraneous materials, and inactivate viruses and break down RNA and DNA into fragments not capable of replication and disease transmission while preserving the biological and mechanical properties. DBM-based pastes and putties are sterilized through the CANCELLE SP process, which is designed to preserve protein activity. The Company's competitors in the conventional allograft market include the Musculoskeletal Transplant Foundation ("MTF"), AlloSource, LifeCell, Inc., a subsidiary of Kinetic Concepts Inc. and LifeNet. Among its competitors in precision machined allograft are MTF, LifeNet and AlloSource. Other companies who process and distribute allograft pastes include Medtronic, AlloSource, Integra, Wright and MTF. Companies who process and distribute xenograft tissue include Synovis, LifeCell, Cook Surgical and Medtronic. The Company considers its competitors in the metal and synthetic markets to include Alphatec, Globus Medical, Inc. (Globus), NuVasive, Inc. (NuVasive) and Orthofix. The Company is subject to federal, state and foreign laws and regulations.
» More Articles for RTIX

Headlines

Articles On GuruFocus.com
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 09 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 05 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 02 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 04 2009 
RTI Biologics Announces 2009 Second Quarter Results Jul 30 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 02 2009 
RTI Biologics Announces 2008 Fourth Quarter Earnings and Year End Earnings and Conference Call Feb 11 2009 

More From Other Websites
RTI Surgical: A Strong Buy on Solid Q1 Results, Raised View - Analyst Blog May 21 2015
Coverage initiated on RTI Surgical by Sidoti May 21 2015
RTI SURGICAL, INC. Financials May 08 2015
IDEXX Laboratories: Q1 Placements Impress, Yet View Down - Analyst Blog May 08 2015
10-Q for RTI Surgical, Inc. May 06 2015
RTI Surgical (RTIX) Jumps: Stock Adds 6.9% in Session - Tale of the Tape May 05 2015
RTI SURGICAL, INC. Files SEC form 10-Q, Quarterly Report May 04 2015
DexCom (DXCM) Q1 Loss Wider Than Expected; Shares Fall - Analyst Blog Apr 30 2015
IDEXX Laboratories Misses on Q1 Earnings, Cuts '15 View - Analyst Blog Apr 29 2015
Merge Healthcare Revenues Top, Earnings Rise Y/Y in Q1 - Analyst Blog Apr 29 2015
3 Reasons Growth Stock Investors Will Love RTI Surgical (RTIX) - Tale of the Tape Apr 27 2015
Cepheid (CPHD) Turns it Around with Q1 Earnings; Guides Up - Analyst Blog Apr 24 2015
RTI Surgical tops Street 1Q forecasts Apr 23 2015
RTI Surgical tops Street 1Q forecasts Apr 23 2015
RTI SURGICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 23 2015
RTI Surgical Announces 2015 First Quarter Results Apr 23 2015
Q1 2015 RTI Surgical Inc Earnings Release - Before Market Open Apr 23 2015
RTI SURGICAL, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Apr 16 2015
RTI Surgical Schedules 2015 First Quarter Earnings and Conference Call for April 23, 2015 Apr 16 2015
Can The Uptrend Continue for RTI Surgical (RTIX)? - Tale of the Tape Apr 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK